TY - JOUR
AU - RECOVERY Collaborative Group
PY - 2025
DA - August
TI - Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
JO - The Lancet Infectious Diseases
DO - https://doi.org/10.1016/S1473-3099(25)00361-5
AB - BACKGROUND: Sotrovimab is a neutralising monoclonal antibody targeting the SARS-CoV-2 spike protein. We aimed to evaluate the efficacy and safety of sotrovimab in the RECOVERY trial, an investigator-initiated, individually randomised, controlled, open-label, adaptive platform trial testing treatments for patients admitted to hospital with COVID-19.
PB - Elsevier
UR - https://www.research.ed.ac.uk/en/publications/c2dc348b-052a-4dda-8909-6d1eb2dd82e9
KW - Coronavirus (COVID-19)
KW - Hospital care
ER